Skip NavigationSkip to Content

Conversion of a polysaccharide to nitric oxide-releasing form. Dual-mechanism anticoagulant activity of diazeniumdiolated heparin

  1. Author:
    Saavedra, J. E.
    Mooradian, D. L.
    Mowery, K. A.
    Schoenfisch, M. H.
    Citro, M. L.
    Davies, K. M.
    Meyerhoff, M. E.
    Keefer, L. K.
  2. Author Address

    Keefer LK NCI, Frederick Canc Res & Dev Ctr, Comparat Carcinogenesis Lab, Chem Sect Frederick, MD 21702 USA NCI, Frederick Canc Res & Dev Ctr, Comparat Carcinogenesis Lab, Chem Sect Frederick, MD 21702 USA NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick Frederick, MD 21702 USA Univ Minnesota, Dept Biomed Engn, Blood & Biocompatibil Res Lab Minneapolis, MN 55455 USA Univ Michigan, Dept Chem Ann Arbor, MI 48109 USA George Mason Univ, Dept Chem Fairfax, VA 22030 USA
    1. Year: 2000
  1. Journal: Bioorganic & Medicinal Chemistry Letters
    1. 10
    2. 8
    3. Pages: 751-753
  2. Type of Article: Article
  1. Abstract:

    We describe heparin/diazeniumdiolate conjugates that generate nitric oxide (NO) at physiological pH. Like the heparin from which they were prepared, they inhibit thrombin-induced blood coagulation. Unlike heparin, they can also inhibit and reverse ADP-induced platelet aggregation (as expected for an NO-releasing agent), suggesting potential utility as dual-action antithrombotics. Published by Elsevier Science Ltd. [References: 9]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel